Lipoprotein(a) in cardiovascular diseases

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Malaguarnera, Michele ^a   Vacante, Marco ^a   Russo, Cristina ^a   Malaguarnera, Giulia ^a   Antic, Tijana ^a   Malaguarnera, Lucia ^a   Bella, Rita ^a   Pennisi, Giovanni ^a   Galvano, Fabio ^a   Frigiola, Alessandro ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; BLOOD CLOTTING FACTOR 12; GELATINASE A; GELATINASE B; LIPOPROTEIN A; NICOTINIC ACID; NITRIC OXIDE; PLASMINOGEN; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR; APOLIPOPROTEIN B100;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; GLYCATION; HEART INFARCTION; HUMAN; NONHUMAN; PLASMINOGEN ACTIVATION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; ANGIOPLASTY; ANIMAL; BRAIN ISCHEMIA; CORONARY RESTENOSIS; ENDOTHELIUM CELL; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PROCEDURES; SMOOTH MUSCLE FIBER; STROKE; VASCULAR SMOOTH MUSCLE; CEREBROVASCULAR ACCIDENT; METHODOLOGY; RESTENOSIS;

ANGIOPLASTY; ANIMALS; APOLIPOPROTEIN B-100; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; ENDOTHELIAL CELLS; HUMANS; LIPOPROTEIN(A); MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; MYOCYTES, SMOOTH MUSCLE; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTORS;

EID: 84874642516     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/650989     Document Type: Review

References (108)

1. Klingenberg R., Hansson G. K., Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. European Heart Journal 2009 30 23 2838 2844 2-s2.0-71549121695 10.1093/eurheartj/ehp477
2. Ross R., Atherosclerosis is-an inflammatory disease. American Heart Journal 1999 138 5 S419 S420 2-s2.0-0032693599
3. Malaguarnera M., Vacante M., Motta M., Malaguarnera M., Li Volti G., Galvano F., Effect of l-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism 2009 58 11 1618 1623 2-s2.0-70449707694 10.1016/j.metabol.2009.05.014
4. Malaguarnera M., Vacante M., Avitabile T., Malaguarnera M., Cammalleri L., Motta M., L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. American Journal of Clinical Nutrition 2009 89 1 71 76 2-s2.0-58149379405 10.3945/ajcn.2008.26251
5. Motta M., Bennati E., Cardillo E., Ferlito L., Passamonte M., Malaguarnera M., The significance of apolipoprotein-B (Apo-B) in the elderly as a predictive factor of cardio-cerebrovascular complications. Archives of Gerontology and Geriatrics 2009 49 1 162 164 2-s2.0-67349222956 10.1016/j.archger.2008.07.001
6. Packard C. J., Apolipoproteins: the new prognostic indicator? European Heart Journal, Supplement 2003 5 D9 D16 2-s2.0-0038202082 10.1016/S1520-765X(03) 90032-0 (Pubitemid 36712281)
7. Sniderman A. D., Furberg C. D., Keech A., Roeters Van Lennep J. E., Frohlich J., Jungner I., Walldius G., Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. The Lancet 2003 361 9359 777 780 2-s2.0-0037333159 10.1016/S0140-6736(03)12663-3 (Pubitemid 36293636)
8. Walldius G., Jungner I., Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. Journal of Internal Medicine 2004 255 2 188 205 2-s2.0-1242340399 10.1046/j.1365-2796.2003.01276.x (Pubitemid 38241363)
9. Utermann G., Menzel H. J., Kraft H. G., Duba H. C., Kemmler H. G., Seitz C., Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. Journal of Clinical Investigation 1987 80 2 458 465 2-s2.0-0023393811
10. Fless G. M., Rolih C. A., Scanu A. M., Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. Journal of Biological Chemistry 1984 259 18 11470 11478 2-s2.0-0021188563 (Pubitemid 14010034)
11. Kostner K. M., Maurer G., Huber K., Stefenelli T., Dieplinger H., Steyrer E., Kostner G. M., Urinary excretion of apo(a) fragments: role in apo(a) catabolism. Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 8 905 911 2-s2.0-0029838377 (Pubitemid 26266886)
12. Mooser V., Marcovina S. M., White A. L., Hobbs H. H., Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. Journal of Clinical Investigation 1996 98 10 2414 2424 2-s2.0-0029832040 (Pubitemid 26394218)
13. Lawn R. M., Wade D. P., Hammer R. E., Chiesa G., Verstuyft J. G., Rubin E. M., Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992 360 6405 670 672 2-s2.0-0026677342 10.1038/360670a0 (Pubitemid 23007679)
14. Kostner K. M., Oberbauer R., Hoffmann U., Stefenelli T., Maurer G., Watschinger B., Urinary excretion of apo(a) in patients after kidney transplantation. Nephrology Dialysis Transplantation 1997 12 12 2673 2678 2-s2.0-0030684058 (Pubitemid 27520693)
15. Mooser V., Marcovina S. M., Wang J., Hobbs H. H., High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay. Clinical Genetics 1997 52 5 387 392 2-s2.0-0031426409 (Pubitemid 28068629)
16. Oida K., Takai H., Maeda H., Takahashi S., Shimada A., Suzuki J., Tamai T., Nakai T., Miyabo S., Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clinical Chemistry 1992 38 11 2244 2248 2-s2.0-0026483286
17. Scanu A. M., Structural basis for the presumptive atherothrombogenic action of lipoprotein(a). Facts and speculations. Biochemical Pharmacology 1993 46 10 1675 1680 2-s2.0-0027373405 10.1016/0006-2952(93)90570-M (Pubitemid 23349013)
18. Motta M., Giugno I., Ruello P., Pistone G., Di Fazio I., Malaguarnera M., Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Medica 2001 92 5 301 305 2-s2.0-0035175836 (Pubitemid 33072399)
19. Galvano F., Malaguarnera M., Vacante M., Motta M., Russo C., Malaguarnera G., D'Orazio N., Malaguarnera L., The physiopathology of lipoprotein (a). Frontiers in Bioscience 2010 2 866 875 2-s2.0-77956624711
20. Galvano F., Li Volti G., Malaguarnera M., Avitabile T., Antic T., Vacante M., Malaguarnera M., Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2009 10 12 1875 1882 2-s2.0-68149181537 10.1517/ 14656560903081745
21. Allen S., Khan S., Tam S. P., Koschinsky M., Taylor P., Yacoub M., Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. FASEB Journal 1998 12 15 1765 1776 2-s2.0-0031729223 (Pubitemid 28553672)
22. Takami S., Yamashita S., Kihara S., Ishigami M., Takemura K., Kume N., Kita T., Matsuzawa Y., Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998 97 8 721 728 2-s2.0-0032478089 (Pubitemid 28135333)
23. Zhao S. P., Xu D. Y., Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thrombosis Research 2000 100 6 501 510 2-s2.0-0034671494 10.1016/S0049-3848(00)00363-7 (Pubitemid 32056302)
24. Tabas I., Li Y., Brocia R. W., Shu Wen Xu, Swenson T. L., Williams K. J., Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. Journal of Biological Chemistry 1993 268 27 20419 20432 2-s2.0-0027257233 (Pubitemid 23278953)
25. Loscalzo J., Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990 10 5 672 679 2-s2.0-0025148799 (Pubitemid 20273337)
26. De Rijke Y. B., Jurgens G., Hessels E. M. A. J., Hermann A., van Berkel T. J. C., In vivo fate and scavenger receptor recognition of oxidized lipoprotein[a] isoforms in rats. Journal of Lipid Research 1992 33 9 1315 1325 2-s2.0-0026709154
27. Chapman M. J., Huby T., Nigon F., Thillet J., Lipoprotein (a): implication in atherothrombosis. Atherosclerosis 1994 110 S69 S75 2-s2.0-0028135480 10.1016/0021-9150(94)05385-V
28. Haque N. S., Zhang X., French D. L., Li J., Poon M., Fallon J. T., Gabel B. R., Taubman M. B., Koschinsky M., Harpel P. C., CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 2000 102 7 786 792 2-s2.0-0033871183 (Pubitemid 30643286)
29. Poon M., Zhang X., Dunsky K., Taubman M. B., Harpel P. C., Apolipoprotein(a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity. Clinical Genetics 1997 52 5 308 313 2-s2.0-0031417438 (Pubitemid 28068619)
30. De Rijke Y. B., Vogelezang C. J. M., Van Berkel T. J. C., Princen H. M. G., Verwey H. F., Van der Laarse A., Bruschke A. V. G., Susceptibility of low-density lipoproteins to oxidation in coronary bypass patients. The Lancet 1992 340 8823 858 859 2-s2.0-0026738307
31. Naruszewicz M., Selinger E., Dufour R., Davignon J., Probucol protects lipoprotein(a) against oxidative modification. Metabolism 1992 41 11 1225 1228 2-s2.0-0026495296 10.1016/0026-0495(92)90013-Z
32. Huby T., Chapman J., Thillet J., Pathophysiological implication of the structural domains of lipoprotein(a). Atherosclerosis 1997 133 1 1 6 2-s2.0-0030797815 10.1016/S0021-9150(97)00111-1 (Pubitemid 27322110)
33. Morishita R., Ishii J., Kusumi Y., Yamada S., Komai N., Ohishi M., Nomura M., Hishida H., Niihashi M., Mitsumata M., Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vasucular wall. Journal of Atherosclerosis and Thrombosis 2009 16 4 410 418 2-s2.0-73249144129
34. Sun H., Unoki H., Wang X., Liang J., Ichikawa T., Arai Y., Shiomi M., Marcovina S. M., Watanabe T., Fan J., Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). Journal of Biological Chemistry 2002 277 49 47486 47492 2-s2.0-0037033101 10.1074/jbc.M205814200 (Pubitemid 36159266)
35. Komai N., Morishita R., Yamada S., Oishi M., Iguchi S., Aoki M., Sasaki M., Sakurabayashi I., Higaki J., Ogihara T., Mitogenic activity of oxidized lipoprotein (a) on human vascular smooth muscle cells. Hypertension 2002 40 3 310 314 2-s2.0-0036712069 10.1161/01.HYP.0000029974.50905.B4 (Pubitemid 35006716)
36. Doucet C., Huby T., Ruiz J., Chapman M. J., Thillet J., Non-enzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis 1995 118 1 135 143 2-s2.0-0028810096 10.1016/0021-9150(95)05600-2
37. Libby P., Inflammation in atherosclerosis. Nature 2002 420 6917 868 874 2-s2.0-0037180771 10.1038/nature01323 (Pubitemid 36019640)
38. Uemura S., Matsushita H., Li W., Glassford A. J., Asagami T., Lee K. H., Harrison D. G., Tsao P. S., Diabetes mellitus enhances vascular matrix metalloproteinase activity role of oxidative stress. Circulation Research 2001 88 12 1291 1298 2-s2.0-0035933381 (Pubitemid 32587846)
39. Eberhardt W., Beeg T., Beck K. F., Walpen S., Gauer S., Böhles H., Pfeilschifter J., Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney International 2000 57 1 59 69 2-s2.0-0033995653 10.1046/j.1523-1755.2000.00808.x (Pubitemid 30227754)
40. Radomski M. W., Palmer R. M. J., Moncada S., Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. The Lancet 1987 2 8567 1057 1058 2-s2.0-0023200487 (Pubitemid 17154788)
41. Aznar J., Estelles A., Breto M., Espana F., Euglobulin clot lysis induced by tissue type plasminogen activator in subjects with increased levels and different isoforms of lipoprotein (a). Thrombosis Research 1993 72 5 459 465 2-s2.0-0027489978 10.1016/0049-3848(93)90247-L (Pubitemid 23345336)
42. Smith E. B., Cochran S., Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis 1990 84 2-3 173 181 2-s2.0-0025147158 (Pubitemid 20360862)
43. Beisiegel U., Niendorf A., Wolf K., Reblin T., Rath M., Lipoprotein(a) in the arterial wall. European Heart Journal 1990 11 174 183 2-s2.0-0025126088 (Pubitemid 20287955)
44. Pellegrino M., Furmaniak-Kazmierczak E., LeBlanc J. C., Cho T., Cao K., Marcovina S. M., Boffa M. B., Côté G. P., Koschinsky M. L., The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. Journal of Biological Chemistry 2004 279 8 6526 6533 2-s2.0-1342325431 10.1074/jbc.M309705200 (Pubitemid 38248787)
45. Cohn J. N., Finkelstein S. M., Abnormalities of vascular compliance in hypertension, aging and heart failure. Journal of Hypertension 1992 10 6 S61 S64 2-s2.0-0026775272
46. Riis Hansen P., Kharazmi A., Jauhiainen M., Ehnholm C., Induction of oxygen free radical generation in human monocytes by lipoprotein(a). European Journal of Clinical Investigation 1994 24 7 497 499 2-s2.0-0028085685 (Pubitemid 2102513)
47. Fan J., Sun H., Unoki H., Shiomi M., Watanabe T., Enhanced atherosclerosis in Lp(a) WHHL transgenic rabbits. Annals of the New York Academy of Sciences 2001 947 362 365 2-s2.0-0035683780 (Pubitemid 34059936)
48. Ichikawa T., Unoki H., Sun H., Shimoyamada H., Marcovina S., Shikama H., Watanabe T., Fan J., Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. American Journal of Pathology 2002 160 1 227 236 2-s2.0-0036141412 (Pubitemid 34052283)
49. Fan J., Watanabe T., Inflammatory reactions in the pathogenesis of atherosclerosis. Journal of Atherosclerosis and Thrombosis 2003 10 2 63 71 2-s2.0-0042510743
50. Kojima S., Harpel P. C., Rifkin D. B., Lipoprotein (a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. Journal of Cell Biology 1991 113 6 1439 1445 2-s2.0-0025896187 (Pubitemid 21909770)
51. Lawn R. M., Pearle A. D., Kunz L. L., Rubin E. M., Reckless J., Metcalfe J. C., Grainger D. J., Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. Journal of Biological Chemistry 1996 271 49 31367 31371 2-s2.0-0029856496 10.1074/jbc.271.49.31367 (Pubitemid 26408587)
52. Etingin O. R., Hajjar D. P., Hajjar K. A., Harpel P. C., Nachman R. L., Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. Journal of Biological Chemistry 1991 266 4 2459 2465 2-s2.0-0025766634 (Pubitemid 21909085)
53. Thillet J., Doucet C., Chapman J., Herbeth B., Cohen D., Faure-Delanef L., Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity evidence from a large population of French centenarians. Atherosclerosis 1998 136 2 389 394 2-s2.0-0032006960 10.1016/S0021-9150(97) 00217-7 (Pubitemid 28133429)
54. Malaguarnera M., Giugno I., Ruello P., Rizzo M., Panebianco M. P., Pistone G., Tomasello F. B., Lipid profile variations in a group of healthy elderly and centenarians. European Review for Medical and Pharmacological Sciences 1998 2 2 75 79 2-s2.0-0032419157 (Pubitemid 29173977)
55. Malaguarnera M., Ruello P., Rizzo M., Receputo G., Rapisarda R., Restuccia N., Pistone G., Lipoprotein (a) levels in centenarians. Archives of Gerontology and Geriatrics 1996 22 1 385 388 2-s2.0-0029813842 (Pubitemid 126658898)
56. Alfthan G., Pekkanen J., Jauhiainen M., Pitkäniemi J., Karvonen M., Tuomilehto J., Salonen J. T., Ehnholm C., Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994 106 1 9 19 2-s2.0-0028219672 10.1016/0021-9150(94)90078-7 (Pubitemid 24103795)
57. Assmann G., Schulte H., Von Eckardstein A., Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. American Journal of Cardiology 1996 77 14 1179 1184 2-s2.0-0029884921 10.1016/S0002-9149(96)00159-2 (Pubitemid 26186958)
58. Coleman M. P., Key T. J. A., Wang D. Y., Hermon C., Fentiman I. S., Allen D. S., Jarvis M., Pike M. C., Sanders T. A. B., A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis 1992 92 2-3 177 185 2-s2.0-0026734174 10.1016/0021-9150(92)90276-M
59. Cremer P., Nagel D., Mann H., Labrot B., Müller-Berninger R., Elster H., Seidel D., Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997 129 2 221 230 2-s2.0-0030972032 10.1016/S0021-9150(96)06030-3 (Pubitemid 27135324)
60. Jauhiainen M., Koskinen P., Ehnholm C., Heikki Frick M., Manttari M., Manninen V., Huttunen J. K., Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991 89 1 59 67 2-s2.0-0025769197
61. Klausen I. C., Sjøl A., Hansen P. S., Gerdes L. U., Møller L., Lemming L., Schroll M., Faergeman O., Apolipoprotein(a) isoforms and coronary heart disease in men A nested case-control study. Atherosclerosis 1997 132 1 77 84 2-s2.0-0030851240 10.1016/S0021-9150(97)00071-3 (Pubitemid 27306742)
62. Ridker P. M., Hennekens C. H., Stampfer M. J., A prospective study of lipoprotein(a) and the risk of myocardial infarction. Journal of the American Medical Association 1993 270 18 2195 2199 2-s2.0-0027366185 10.1001/jama.270.18. 2195 (Pubitemid 23323634)
63. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H., Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. British Medical Journal 1990 301 6763 1248 1251 2-s2.0-0025633291
64. Schaefer E. J., Lamon-Fava S., Jenner J. L., McNamara J. R., Ordovas J. M., Davis C. E., Abolafia J. M., Lippel K., Levy R. I., Lipoprotein(a) levels and risk of coronary heart disease in men: the lipid research clinics coronary primary prevention trial. Journal of the American Medical Association 1994 271 13 999 1003 2-s2.0-0028316960 10.1001/jama.271.13.999 (Pubitemid 24099920)
65. Sigurdsson G., Baldursdottir A., Sigvaldason H., Agnarsson U., Thorgeirsson G., Sigfusson N., Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. American Journal of Cardiology 1992 69 16 1251 1254 2-s2.0-0026719901 10.1016/0002-9149(92)91215-P
66. Wald N. J., Law M., Watt H. C., Wu T., Bailey A., Myron Johnson A., Craig W. Y., Ledue T. B., Haddow J. E., Apolipoproteins and ischaemic heart disease: implications for screening. The Lancet 1994 343 8889 75 79 2-s2.0-0028156929 10.1016/S0140-6736(94)90814-1 (Pubitemid 24019347)
67. Wild S. H., Fortmann S. P., Marcovina S. M., A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City project participants. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 5 239 245 2-s2.0-0030912813 (Pubitemid 27098179)
68. Bostom A. G., Gagnon D. R., Cupples L. A., Wilson P. W. F., Jenner J. L., Ordovas J. M., Schaefer E. J., Castelli W. P., A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation 1994 90 4 1688 1695 2-s2.0-0027948506 (Pubitemid 24320915)
69. Bostom A. G., Cupples L. A., Jenner J. L., Ordovas J. M., Seman L. J., Wilson P. W. F., Schaefer E. J., Castelli W. P., Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. Journal of the American Medical Association 1996 276 7 544 548 2-s2.0-0029740582 10.1001/jama.276.7.544 (Pubitemid 26272299)
70. Cantin B., Gagnon F., Moorjani S., Després J. P., Lamarche B., Lupien P. J., Dagenais G. R., Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study. Journal of the American College of Cardiology 1998 31 3 519 525 2-s2.0-18144438859 10.1016/S0735-1097(97)00528-7 (Pubitemid 28144115)
71. Cressman M. D., Heyka R. J., Paganini E. P., O'Neil J., Skibinski C. I., Hoff H. F., Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992 86 2 475 482
72. Kronenberg F., Kronenberg M. F., Kiechl S., Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999 100 11 1154 1160 (Pubitemid 29426589)
73. Dahlén G. H., Weinehall L., Stenlund H., Jansson J. H., Hallmans G., Huhtasaari F., Wall S., Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. Journal of Internal Medicine 1998 244 5 425 430 2-s2.0-0031791037 10.1046/j.1365-2796.1998.00422.x (Pubitemid 28513131)
74. Nguyen T. T., Ellefson R. D., Hodge D. O., Bailey K. R., Kottke T. E., Abu-Lebdeh H. S., Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997 96 5 1390 1397 2-s2.0-0030774676 (Pubitemid 27375327)
75. Hoogeveen R. C., Gambhir J. K., Gambhir D. S., Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. Journal of Lipid Research 2001 42 4 631 638 (Pubitemid 32367006)
76. Dirisamer A., Widhalm K., Lipoprotein(a) as a potent risk indicator for early cardiovascular disease. Acta Paediatrica 2002 91 12 1313 1317 (Pubitemid 36174055)
77. Wilson S. H., Celermajer D. S., Nakagomi A., Wyndham R. N., Janu M. R., Freedman S. B., Vascular risk factors correlate to the extent as well as the severity of coronary atherosclerosis. Coronary Artery Disease 1999 10 7 449 453 2-s2.0-0033435115 (Pubitemid 30011900)
78. Schwartzman R. A., Cox I. D., Poloniecki J., Crook R., Seymour C. A., Kaski J. C., Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris. Journal of the American College of Cardiology 1998 31 6 1260 1266 2-s2.0-0032080742 10.1016/S0735-1097(98)00096-5 (Pubitemid 28219115)
79. Imhof A., Rothenbacher D., Khuseyinova N., Hoffmeister A., Maerz W., Nauck M., Scharnagl H., Koenig W., Brenner H., Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease. European Journal of Cardiovascular Prevention and Rehabilitation 2003 10 5 362 370 2-s2.0-0345763178 10.1097/01.hjr.0000087080.83314.be (Pubitemid 38037251)
80. Rader D. J., Hoeg J. M., Brewer H. B., Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Annals of Internal Medicine 1994 120 12 1012 1025 2-s2.0-0028289634 (Pubitemid 24169282)
81. Motta M., Giugno I., Bosco S., Pistone G., Ruello P., Maugeri D., Malaguarnera M., Serum lipoprotein(a) changes in acute myocardial infarction. Panminerva Medica 2001 43 2 77 80 2-s2.0-0035378794 (Pubitemid 33636951)
82. Desmarais R. L., Sarembock I. J., Ayers C. R., Vernon S. M., Powers E. R., Gimple L. W., Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995 91 5 1403 1409 2-s2.0-0028941169
83. Hoff H. F., Beck G. J., Skibinski C. I., Jurgens G., O'Neil J., Kramer J., Lytle B., Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988 77 6 1238 1244 2-s2.0-0023885945
84. Barbir M., Kushwaha S., Hunt B., Macken A., Thompson G. R., Mitchell A., Robinson D., Yacoub M., Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. The Lancet 1992 340 8834-8835 1500 1502 2-s2.0-0026496003 10.1016/0140-6736(92)92756-6
85. Maher V. M. G., Brown B. G., Marcovina S. M., Hillger L. A., Zhao X. Q., Albers J. J., Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). Journal of the American Medical Association 1995 274 22 1771 1774 2-s2.0-0028877052 10.1001/jama.274.22.1771
86. Patsch W., Gotto A. M., Apolipoproteins: pathophysiology and clinical implications. Methods in Enzymology 1996 263 3 32 2-s2.0-0029563648 (Pubitemid 126691161)
87. Stein J. H., Rosenson R. S., Lipoprotein Lp(a) excess and coronary heart disease. Archives of Internal Medicine 1997 157 11 1170 1176 2-s2.0-0030987764 (Pubitemid 27251643)
88. Igarashi Y., Aizawa Y., Satoh T., Konno T., Ojima K., Aizawa Y., Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty-with special reference to the admission concentration of lipoprotein (a). Circulation Journal 2003 67 7 605 611 2-s2.0-0038268819 (Pubitemid 36834389)
89. Terres W., Tatsis E., Pfalzer B., Beil F. U., Beisiegel U., Hamm C. W., Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995 91 4 948 950 2-s2.0-0028910744
90. Tamura A., Watanabe T., Mikuriya Y., Nasu M., Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction. British Heart Journal 1995 74 4 365 369 2-s2.0-0028980007
91. Morita Y., Himeno H., Yakuwa H., Usui T., Serum lipoprotein(a) level and clinical coronary stenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circulation Journal 2006 70 2 156 162 2-s2.0-31644435758 10.1253/circj.70.156 (Pubitemid 43170125)
92. Craig W. Y., Neveux L. M., Palomaki G. E., Cleveland M. M., Haddow J. E., Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clinical Chemistry 1998 44 11 2301 2306 2-s2.0-0031729386 (Pubitemid 28511752)
93. Danesh J., Collins R., Peto R., Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000 102 10 1082 1085 2-s2.0-0034609562
94. Gaw A., Murray H. M., Brown E. A., Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis 2005 180 2 381 388 2-s2.0-23044437618 10.1016/j.atherosclerosis. 2004.12.015 (Pubitemid 41072910)
95. Sandholzer C., Saha N., Kark J. D., Rees A., Jaross W., Dieplinger H., Hoppichler F., Boerwinkle E., Utermann G., Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arteriosclerosis and Thrombosis 1992 12 10 1214 1226 2-s2.0-0026700306
96. Edelberg J. M., Reilly C. F., Pizzo S. V., The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1: the effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). Journal of Biological Chemistry 1991 266 12 7488 7493 2-s2.0-0025788587 (Pubitemid 21906391)
97. Grainger D. J., Kirschenlohr H. L., Metcalfe J. C., Weissberg P. L., Wade D. P., Lawn R. M., Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993 260 5114 1655 1658 2-s2.0-0027220011 (Pubitemid 23247149)
98. Dahlén G., Lipoprotein (a) as a risk factor for atherosclerotic diseases. Arctic Medical Research 1998 47 458 461 2-s2.0-18744426366
99. Emerging Risk Factors Collaboration, Erqou S., Kaptoge S., Perry P. L., Di Angelantonio E., Thompson A., White I. R., Marcovina S. M., Collins R., Thompson S. G., Danesh J., Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Journal of the American Medical Association 2009 302 4 412 423 2-s2.0-67651210632 10.1001/jama.2009.1063
100. Kamstrup P. R., Benn M., Tybjærg-Hansen A., Nordestgaard B. G., Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008 117 2 176 184 2-s2.0-38049177286 10.1161/CIRCULATIONAHA.107.715698
101. American Association for Clinical Chemistry, Emerging Biomarkers for Primary Prevention of Cardiovascular Disease and Stroke. 2009, http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/risk/ Documents/EmergingCV-RiskFactors09.pdf
102. Milionis H. J., Winder A. F., Mikhailidis D. P., Lipoprotein (a) and stroke. Journal of Clinical Pathology 2000 53 7 487 496 2-s2.0-0033935156 10.1136/jcp.53.7.487 (Pubitemid 30432104)
103. Nordestgaard B. G., Chapman M. J., Ray K., Borén J., Andreotti F., Watts G. F., Ginsberg H., Amarenco P., Catapano A., Descamps O. S., Fisher E., Kovanen P. T., Kuivenhoven J. A., Lesnik P., Masana L., Reiner Z., Taskinen M. R., Tokgözoglu L., Tybjærg-Hansen A., Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 2010 31 23 2844 2853 2-s2.0-78649888517 10.1093/eurheartj/ehq386
104. Riches K., Porter K. E., Lipoprotein(a): cellular effects and molecular mechanisms. Cholesterol 2012 2012 10 923289 10.1155/2012/923289
105. Dubé B J., Boffa M. B., Hegele R. A., Koschinsky M. L., Lipoprotein(a): more interesting than ever after 50 years. Current Opinion in Lipidology 2012 23 133 140
106. Tsimikas S., Hall J. L., Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. Journal of the American College of Cardiology 2012 60 716 721
107. Momiyama Y., Ohmori R., Fayad Z. A., Tanaka N., Kato R., Taniguchi H., Nagata M., Ohsuzu F., Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis. Atherosclerosis 2012 222 1 241 244
108. Momiyama Y., Ohmori R., Fayad Z. A., Tanaka N., Kato R., Taniguchi H., Nagata M., Ohsuzu F., Associations between serum lipoprotein(a) levels and the severity of coronary and aortic atherosclerosis. Atherosclerosis 2012 222 1 241 244